ITCI
Intra-Cellular Therapies Inc.
ITCI
ITCI
Delisted
ITCI was delisted on the 1st of April, 2025.
240 hedge funds and large institutions have $4.88B invested in Intra-Cellular Therapies Inc. in 2022 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 90 increasing their positions, 64 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
36% more capital invested
Capital invested by funds: $3.59B → $4.88B (+$1.29B)
16% more funds holding
Funds holding: 207 → 240 (+33)
Holders
240
Holding in Top 10
13
Calls
$33.7M
Puts
$16.4M
Top Buyers
| 1 | +$249M | |
| 2 | +$56.9M | |
| 3 | +$55.8M | |
| 4 |
BlackRock
New York
|
+$45.8M |
| 5 |
Holocene Advisors
New York
|
+$44.2M |
Top Sellers
| 1 | -$46.3M | |
| 2 | -$38.3M | |
| 3 | -$28.6M | |
| 4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$25.7M |
| 5 |
Two Sigma Investments
New York
|
-$14.5M |